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Cardiac hypertrophy and remodeling in relation to ACE and Cardiovascular disease causes significant morbidity
angiotensinogen genes genotypes in Chinese dialysis patients. and mortality in patients with end-stage renal disease
Background. Genetic polymorphisms of the angiotensino- (ESRD). A cross-section survey showed that left ventric-
gen (AGT) and angiotensin-converting enzyme (ACE) genes
ular hypertrophy (LVH) is highly prevalent in patientsare associated with increased risk of hypertension and left
with ESRD [1] and is a strong predictor for mortality inventricular hypertrophy (LVH) in hypertensive subjects. How-
patients on maintenance dialysis [2]. On the other hand,ever, the extent to which these polymorphisms are related to
LVH and remodeling in dialysis patients remains unknown. abnormal left ventricular (LV) geometry is also associ-
Methods. Two hundred and forty-six end-stage renal disease ated with poor outcome in chronic dialysis patients [3]
(ESRD) patients on peritoneal dialysis and 183 control sub- and predicts cardiovascular events in hypertensive pa-
jects, all of Chinese origin, were genotyped for the ACE inser-
tients [4, 5]. The pathogenesis of LVH in dialysis patientstion/deletion (I/D) and the AGT M235T gene polymorphisms.
involved a multitude of risk factors, including systolicLeft ventricular mass index (LVMi) and relative wall thickness
hypertension, anemia, increasing age, and duration ofwere measured using echocardiography.
Results. Prevalence of ACE DD and AGT TT genotype was dialysis [6, 7]. Recent study showed that the renin-angio-
14% and 83%, respectively, in ESRD patients and did not tensin system (RAS) has an independent direct role in
differ significantly from controls. A total percentage of 95% promoting cardiac growth and remodeling through blood
of our patients had LVH (171 with concentric and 63 with ec- pressure regulation as well as through the local cardiac
centric hypertrophy). Adjusting for age, gender, body mass in-
RAS. Expression of angiotensin II is up-regulated in thedex, duration of dialysis, diabetes, renal diagnosis, hematocrit,
presence of volume or pressure overload [8, 9], resultingsystolic and diastolic blood pressure, dialysis urea clearance,
in enhanced expression of transforming growth factor-residual glomerular filtration rate, and use of converting enzyme
inhibitors or angiotensin receptor blockers, AGT TT genotype (TGF-) and proto-oncogenes that modulate cardiac
remained independently associated with greater LVMi (coeffi- growth [10,11]. Other than neurohormonal mediators,
cient  28.73; 95% CI, 5.72 to 51.75; P  0.015) and relative there is evidence that LV mass is also under the influence
wall thickness (coefficient  0.072; 95% CI, 0.022 to 0.122; of genetic factors [12, 13], indicating that LVH is a com-P  0.005) than MT/MM genotypes. LVMi and relative wall
plex phenotype, modulated by the interaction of genetic,thickness did not differ significantly among patients with DD,
environmental, and neurohormonal factors.DI, and II genotypes. No statistical significant interaction was
noted between ACE and AGT gene polymorphism in relation Cloning of the human genes encoding for the angioten-
to LVMi and relative wall thickness. sin-converting enzyme (ACE) and angiotensinogen (AGT)
Conclusion. Polymorphism of the AGT M235T gene but not has led to the discovery of several polymorphisms with
ACE I/D gene is associated with greater LVMi and relative regulatory roles in the RAS [14]. The insertion/deletion
wall thickness, indicating more concentric LVH, in Chinese
(I/D) polymorphism in intron 16 of the ACE gene ac-peritoneal dialysis patients. Possible synergistic effects between
counts for approximately 50% of the interindividual vari-AGT and ACE gene polymorphism require further evaluation
ations in plasma ACE levels with the highest ACE levelsin a larger population.
found in DD homozygotes and the lowest in the II homo-
zygotes [15]. DD genotype was associated with an in-
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tween DD genotype and LVH has not been reported in ers flanking the polymorphic region of intron 16 with
the following primer sequences: 5-CTG GAG ACCChinese population [20, 21] and may be related to very
low prevalence of the DD genotype in Chinese (13% to ACT CCC ATC CTT TCT-3 and 5-GAT GTG GCC
ATC ACA TTC GTC AGA T-3. Reactions were car-15%) compared to Caucasian (35%) [22]. On the other
hand, the frequency of T allele of the AGT M235T gene ried out in 50 L volumes under standard conditions
[3 mmol/L MgCl2, 50 mol/L of each desoxynucleosideis much higher in Chinese (70% to 73%) [20, 21] than
Caucasian (10% to 24%) [22, 23]. The AGT M235T triphosphate (dNTP), 10 mmol/L Tris/HCl, 50 mmol/L
KCl, 0.2 mol/L primers, 1 U Taq DNA polymerase pergene polymorphism has functional significance in that
TT genotype is associated with increased serum AGT sample] with a Cetus thermocycler and 1 minute denatur-
ing at 94C, 1 minute annealing at 58C, and 1 minutelevels and greater risk of hypertension and coronary
artery disease [24, 25]. extending at 72C for a total of 30 cycles. Electrophoresis
of the amplified products in 2% agarose gel allowedGiven the marked interethnic difference in the frequen-
cies of the RAS polymorphisms and the high prevalence detection of a 190 base pair (bp) fragment (deletion, D
allele) and of a 490 bp fragment (insertion, I allele).of LVH in dialysis population, this study was carried out
to determine the relationships between polymorphisms Mistyping between the DD and DI genotypes was over-
come by a second, allele-specific PCR, which identifiedof the ACE I/D gene and AGT M235T gene and LV
parameters in Chinese ESRD patients treated by perito- the presence or absence of I allele.
The AGT M235T gene polymorphism was detectedneal dialysis.
by PCR amplification followed by restriction enzyme diges-
tion [25]. The amplification used the following primers: 5-
METHODS
CAG GGT GCT GTC CAC ACT GGA CCC-3 and
Study population 5-CCG TTT GTG CAG GGC CTG GCT CTC T-3.
Reactions were carried out in 25 L volumes under stan-The population of this study included 246 continuous
ambulatory peritoneal dialysis (CAPD) patients (126 men dard conditions (1.5 mmol/L MgCl2, 50 mol/L of each
dNTP, 10 mmol/L Tris/HCl, 50 mmol/L KCl, 1 mol/Land 120 women), all of Chinese origin, who had been
on regular dialysis treatment for at least 3 months at the primers, 1 U Taq DNA polymerase per sample) with a
Cetus thermocycler and 1 minute denaturing at 94C, 1Prince of Wales Hospital in Hong Kong were considered
eligible for the study and represented about 88% of the minute annealing at 68C and 1 minute extending at 72C
for a total of 30 cycles. The amplified product was thenwhole peritoneal dialysis population in our hospital. Pa-
tients excluded from this study included those with un- digested by 1 U Tth III at 65C for 3 hours, and the
digested fragments were separated by electrophoresis inderlying valvular heart disease, congenital heart disease,
and those who refused to participate. There were 183 2.5% agarose gel, which revealed a nondigested band of
165 bp (M allele) and/or of 141 bp (T allele) and 24 bp.healthy Hong Kong Chinese subjects with no underlying
diabetes, hypertension, or renal disease who were recruited
Echocardiographyas controls. The study was approved by the Clinical Re-
search Ethics Committee of the Chinese University of Echocardiography was performed with the patient ly-
ing in the left lateral decubitus position, using a GE-Hong Kong. Informed consent was obtained from all
study subjects. VingMed System V echocardiographic machine (GE-
VingMed Sound AB, Horten, Norway) and a 3.5 mHz
Extraction of deoxyribonucleic acid (DNA) multiphase-array probe by a single experienced cardiolo-
gist blinded to all clinical details of patients. Echocardio-Peripheral blood (10 mL) was collected on ethylenedi-
aminetetraacetic acid (EDTA) (pH 8.0) in all patients. graphic measurements of left ventricular mass (LVM),
interventricular septal thickness (IVSd), posterior wallGenomic DNA was extracted from peripheral blood leu-
kocytes using the Qiagen DNA prep kit (Qiagen, Chats- thickness (PWd), and left ventricular end-diastolic diam-
eters (LVedd) were made at end diastole according toworth, CA, USA). DNA concentration was calculated from
absorbance at 260 nm measured by a spectrophotometer, the guidelines of the American Society of Echocardiog-
raphy [26, 27]. Individual values for LVM were indexedDU 650, Beckman Instrument (Fullerton, CA, USA).
Purity of DNA was estimated by the ratio of absorbance by body surface area (LVMi) and expressed as g/m2. LVH
was defined as LVMi 131g/m2 in men and 100 g/m2at 260/280 nm.
in women in accordance with Framingham criteria [28].
Determination of ACE and AGT genotypes
Patterns of LV geometryThe ACE genotype was determined by polymerase
chain reaction (PCR), using the primers and methods Relative wall thickness (RWT) was measured at end
diastole as the ratio of two times PWd to LVedd [4].described by Cambien et al [18]. Briefly, the ACE I/D
gene polymorphism was determined by PCR using prim- RWT of 0.45 or above was considered to be abnormally
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Table 1. Distributions of the ACE I/D and AGT M235T genotypeelevated. Patients were categorized into four different
and allele frequencies among Chinese patients with end-stage renal
patterns of LV geometry according to the values of LVMi disease and normal controls
and RWT. Patients with normal LVMi were considered
Controlto have normal LV geometry if their RWT was normal subjects ESRD patients P value
(0.45) or concentric remodeling if their RWT was in-
Number 183 246
creased (0.45). Those with increased LVMi were con- ACE genotype
DD 24 (13) 36 (15) NSsidered to have concentric or eccentric LVH if their
ID 88 (48) 104 (42)RWT was elevated ( 0.45) or normal (0.45), respec-
II 71 (39) 106 (43)
tively. ACE allele frequency
D 0.37 0.36 NS
I 0.63 0.64Clinical and hemodynamic parameters
AGT M235T genotype
Demographic data, including age, gender, underlying TT 128 (70) 174 (70) NS
MT 46 (25) 68 (28)renal diagnosis, duration on dialysis, presence of diabetes,
MM 9 (5) 4 (2)ischemic heart disease, history of heart failure, and athero-
AGT allele frequency
sclerotic vascular complications, were recorded. Athero- T 0.82 0.84 NS
M 0.18 0.16sclerotic vascular complications included the presence of
angina, previous myocardial infarction, with or without Abbreviations are: ACE, angiotensin-converting enzyme; AGT, angiotensino-
gen; I/D, insertion/deletion.coronary artery bypass surgery or stenting, cerebrovascu-
lar accident, transient ischemic attack, or peripheral vas-
cular disease with or without amputation. Body mass
index was calculated as body weight in kg/body height hypertensive nephrosclerosis, systolic and diastolic blood
in m2. Systolic and diastolic blood pressure measured pressure, hematocrit, dialysis urea clearance, residual
every follow-up at 8 weekly intervals were averaged for GFR, and use of converting enzyme inhibitor or angio-
the 12 months preceding echocardiography. Hemoglobin tensin receptor antagonist. Both ACE and AGT geno-
and hematocrit measured at 8 weekly intervals were av- types were recoded into binary variables (that is, 0 and
eraged for the 12 months preceding echocardiography. 1) before entering the regression model. Interaction be-
Types of antihypertensive medication, including angio-
tween the ACE DD and the AGT TT genotype was
tensin-converting enzyme (ACE) inhibitor or angioten-
tested by including the “interaction term” in the regres-
sin receptor antagonist taken by patients were recorded.
sion models. A P value of less than 0.05 (two-tailed) was
considered statistically significant.Dialysis parameters
Total weekly urea clearance (Kt/V) and creatinine
clearance were measured using standard methods [29]. RESULTS
Dialysate creatinine concentration was corrected for in- ACE I/D and AGT M235T gene polymorphism of
terference by glucose according to reference formula deter- ESRD patients and healthy controls
mined in our laboratory [30]. Contribution of urea clear-
The ACE I/D and AGT M235T genotypes and alleleance by peritoneal dialysis was estimated separately.
frequencies in Chinese control subjects and ESRD pa-Residual glomerular filtration rate (GFR) was calculated
tients are shown in Table 1. All genotype frequenciesas an average of the 24-hour urinary urea and creatinine
were in agreement with the frequencies predicted byclearance [31]. Total body water (V) was derived using
the Hardy-Weinberg equilibrium. The frequencies of theWatson formula [32].
ACE and AGT genotypes were not different between
Statistical analysis control subjects and ESRD patients. A very high fre-
quency of the AGT T allele (80%) was noted in Chi-Statistical analysis was performed using SPSS statisti-
nese. Only five patients in control group and two patientscal software version 10.0 (Chicago, IL, USA). Continu-
in ESRD group have MM genotype. In view of the lowous data were expressed as mean	 SD while categorical
prevalence of MM genotype in Chinese, patients of MMdata as number (%). Comparisons between groups were
genotype were combined with MT genotype as a groupperformed using one-way ANOVA (analysis of vari-
for comparison with patients of TT genotype.ance) or chi-squared test, as appropriate, and multiple
comparisons adjusted by Bonferroni post-hoc test. The
Clinical, biochemical, dialytic, and echocardiographicindependent associations of the ACE DD and the AGT
characteristics of ESRD patientsTT genotypes with LVMi and RWT were evaluated us-
Among the 246 patients, 73 patients (30%) had diabe-ing multiple linear regression analysis with adjustments
tes mellitus. The prevalence of diabetes in our studyfor confounding covariates. These included age, gender,
body mass index, duration, diabetes mellitus, underlying population was representative of the Hong Kong perito-
Wang et al: ACE and angiotensinogen gene and cardiac hypertrophy in dialysis patients1902
Table 2. Clinical, biochemical, dialytic, and echocardiographic characteristics of end-stage renal disease (ESRD) patients with the DD, DI,
and II genotypes of the ACE gene
DD (N  36) DI (N  104) II (N  106) P value
Clinical and demographic parameters
Age years 55	12 56	12 54	12 0.386
Sex male/female 24/12 54/50 48/58 0.084
Duration of dialysis months 39	30 34	26 39	32 0.346
Body mass index kg/m2 22	3 23	3 24	4 0.128
Diabetes mellitus, number (%) 7 (19) 29 (28) 37 (35) 0.187
Renal diagnosis, number (%)
Chronic glomerulonephritis 14 (39) 30 (29) 39 (37) 0.027
Diabetic nephropathy 6 (17) 22 (21) 31 (29)
Hypertensive nephrosclerosis 9 (25) 12 (11) 9 (9)
Other causes 7 (19) 40 (39) 27 (26)
Ischemic heart disease, number (%) 7 (19) 18 (17) 21 (20) 0.891
Atherosclerotic vascular disease, number (%) 7 (19) 21 (20) 26 (25) 0.694
History of heart failure, number (%) 17 (47) 33 (32) 46 (43) 0.123
Systolic blood pressure mm Hg 146	15 147	18 147	17 0.919
Diastolic blood pressure mm Hg 84	11 82	9 83	11 0.609
Number of anti-hypertensives 1.6	1.0 1.6	1.0 1.6	1.0 0.935
Use of CEI or ARB, number (%) 10 (28) 25 (24) 30 (28) 0.767
Biochemical parameters
Hemoglobin g/dL 9.4	1.6 9.2	1.4 9.3	1.6 0.851
Hematocrit (%) 27.5	4.5 27.3	4.1 27.9	5.4 0.589
Use of erythropoietin, number (%) 15 (42) 41 (39) 41 (39) 0.951
Dialysis parameters
Total weekly Kt/V 1.76	0.43 1.83	0.45 1.80	0.42 0.698
Weekly peritoneal dialysis Kt/V 1.47	0.35 1.49	0.39 1.55	0.35 0.373
Total weekly creatinine clearance L/week/1.73 m2 58	24 60	23 53	18 0.103
Residual GFR mL/min/1.73 m2 0.49 (0, 2.13) 0.74 (0, 2.23) 0.63 (0, 1.66) 0.312
Echocardiographic parameters
Left ventricular mass index g/m2 233	82 225	86 223	85 0.827
LVedd mm 4.94	0.74 5.05	0.90 5.01	0.80 0.796
IVSd cm 1.50	0.27 1.49	0.40 1.47	0.39 0.858
LVPWd cm 1.36	0.33 1.28	0.28 1.33	0.28 0.182
RWT 0.57	0.18 0.52	0.14 0.55	0.18 0.216
Abbreviations are: CEI, converting-enzyme inhibitor; ARB, angiotensin-receptor blocker; Kt/V, urea clearance; GFR, glomerular filtration rate; LVedd, left
ventricular end-diastolic diameter; IVSd, interventricular septal thickness in diastole; LVPWd, left ventricular posterior wall thickness in diastole; RWT, relative wall
thickness.
neal dialysis population [29]. Our patients were dialyzed slightly more men (P  0.084), fewer diabetics (P 
0.187), and more patients with hypertensive nephroscle-for a mean 	 SD duration of 37 	 29 months. The
mean 	 SD body weight and height was 58 	 11 kg and rosis as the cause of ESRD (P  0.027) among those of
DD genotype than DI and II genotypes. Weekly Kt/V,1.58 	 0.08 m, respectively. The mean hemoglobin and
hematocrit were 9.3 	 1.5 g/dL and 0.28 	 0.05%. The creatinine clearance, and residual GFR were not signifi-
cantly different for patients with DD, DI, and II geno-average total weekly and peritoneal dialysis Kt/V was
1.87 	 0.46 and 1.53 	 0.35, respectively. Total weekly types. Echocardiographic parameters, including LVMi,
LVedd, IVSd, LVPWd, and RWT, did not differ signifi-creatinine clearance was 59 	 24 L/week/1.73 m2. Resid-
ual GFR was 1.39 	 1.76 mL/min/1.73 m2. Mean systolic cantly among the three groups.
and diastolic blood pressure were 147 	 17 and 83 	 10
Clinical, biochemical, dialytic, and echocardiographicmm Hg, respectively. The mean LVMi was 226	 84 g/m2.
parameters in relation to AGT M235TPrevalence of LVH was 95% with 171 patients (69.5%)
gene polymorphismshowing concentric and 63 patients (25.6%) showing ec-
centric LV hypertrophy. Only 12 patients had normal Table 3 summarizes the clinical, biochemical, dialytic,
and echocardiographic features of patients with differentLVMi, among which five patients had normal LV geome-
try and seven patients had concentric remodeling. AGT genotypes. There were more diabetics having
MT/MM than TT genotypes (P  0.042). Patients with
Clinical, biochemical, dialytic, and echocardiographic TT genotype showed a trend toward higher hemoglobin
parameters in relation to ACE I/D genotypes and hematocrit. Systolic and diastolic blood pressure was
not significantly different between patients with TT andThe clinical, biochemical, dialytic, and echocardio-
graphic characteristics of ESRD patients with DD, DI, MT/MM genotypes. Weekly Kt/V, creatinine clearance,
and residual GFR did not differ significantly betweenand II genotypes were shown in Table 2. There were
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Table 3. Clinical, biochemical, dialytic, and echocardiographic characteristics of Chinese end-stage renal disease (ESRD) patients with TT
and MT/MM genotypes of the AGT M235T gene
TT (N  174) MT/MM (N  72) P value
Clinical and demographic characteristics
Age year 54	12 57	13 0.088
Sex male/female 89/85 37/35 0.973
Duration of dialysis months 36	27 40	34 0.291
Body mass index kg/m2 23	3 23	3 0.882
Diabetes mellitus, number (%) 45 (26) 28 (39) 0.042
Renal diagnosis, number (%)
Chronic glomerulonephritis 63 (36) 20 (28) 0.110
Diabetic nephropathy 35 (20) 24 (33)
Hypertensive nephrosclerosis 24 (14) 6 (8)
Other causes 52 (30) 22 (31)
Ischemic heart disease, number (%) 34 (20) 12 (17) 0.599
Atherosclerotic vascular disease, number (%) 40 (23) 14 (19) 0.541
History of heart failure, number (%) 66 (38) 30 (42) 0.585
Systolic blood pressure mm Hg 147	16 147	17 0.945
Diastolic blood pressure mm Hg 81	10 83	10 0.175
Number of antihypertensives 1.5	1.0 1.6	1.0 0.406
Use of CEI or ARB, number (%) 47 (27) 22 (31) 0.573
Biochemical parameters
Hemoglobin g/dL 9.6	1.8 9.2	1.3 0.059
Hematocrit (%) 27.5	4.5 27.3	4.1 0.093
Use of erythropoietin, number (%) 75 (43) 22 (31) 0.067
Dialysis parameters
Total weekly Kt/V 1.82	0.46 1.79	0.39 0.707
Weekly peritoneal dialysis Kt/V 1.53	0.37 1.49	0.37 0.477
Total weekly creatinine clearance L/week/1.73 m2 56	21 58	22 0.534
Residual GFR mL/min/1.73 m2 0.64 (0, 1.89) 0.73 (0, 2.03) 0.521
Echocardiographic parameters
Left ventricular mass index g/m2 232	89 211	70 0.065
LVedd mm 4.99	0.86 5.08	0.77 0.435
IVSd cm 1.52	0.40 1.39	0.30 0.011
LVPWd cm 1.34	0.30 1.24	0.25 0.012
RWT 0.56	0.18 0.50	0.13 0.016
Abbreviations are: Kt/V, urea clearance; GFR, glomerular filtration rate; LVedd, left ventricular end-diastolic diameter; IVSd, interventricular septal thickness in
diastole; LVPWd, left ventricular posterior wall thickness in diastole; RWT, relative wall thickness.
patients with TT and MT/MM genotypes. Patients with DISCUSSION
TT genotype had greater LVMi, although not reaching This study was the first to demonstrate an association
statistical significance, as well as greater IVSd, LVPWd, of the TT genotype of the AGT gene with LV mass and
and RWT than those with MT/MM genotypes. Among LV remodeling in Chinese ESRD patients, independent
patients with increased LVMi, the prevalence of TT ge- of other covariates. However, no significant association
notype was higher for patients with concentric versus was noted between DD genotype of the ACE gene and
eccentric LVH (76% vs. 60%; P  0.018). LV mass or LV geometric patterns. Like LVH, LV geo-
metric pattern was an important prognostic indicator
ACE I/D and AGT M235T gene polymorphisms in [3–5]. Presence of LVH with abnormal RWT, indicating
relation to LV mass index and relative wall thickness concentric LVH, conferred the highest risk for all-cause
Using multiple linear regression analysis, male gender, mortality and cardiac mortality [3–5]. However, concen-
body mass index, duration of dialysis, hematocrit, and tric remodeling was not associated with an increased risk
systolic blood pressure were each significantly related to of death [33], suggesting that the predictive value of
LVMi. Only duration of dialysis was significantly related RWT was not as strong as LV mass.
to RWT. ACE DD genotype was not significantly related The relationships between the ACE gene polymor-
to LVMi and RWT. AGT TT genotype was indepen- phism and LV mass and remodeling had been extensively
dently associated with an increased LVMi (coefficient  investigated in different populations, but yielded con-
28.73; 95% CI, 5.72 to 51.75; P  0.015; Table 4) and flicting results. Although some studies showed significant
RWT (coefficient  0.072; 95% CI, 0.022 to 0.122; P  association between the DD genotype of the ACE gene
0.005; Table 5). No significant interaction was observed and LV mass and remodeling in nonrenal failure popula-
between ACE DD genotype and AGT TT genotype in tion [16, 19, 34–36], other showed no genetic linkage
between the ACE gene and LV mass [37]. Among therelation to LVMi (P  0.85) and RWT (P  0.14).
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Table 4. Multiple linear regression analysis showing a significant cross-section relationship between the TT genotype of AGT M235T gene
and LV mass index with adjustment for confounding covariates
Variable Unit change Coefficient 95% Confidence interval P value
Age 1 year 0.64 
0.34, 1.62 0.201
Gender Female 
23.79 
47.33, 
0.24 0.048
Body mass index 1 kg/m2 4.19 0.93, 1.11 0.009
Duration of dialysis 1 month 0.49 0.09, 0.89 0.017
Diabetes mellitus — 
4.32 
30.43, 21.80 0.745
Hypertensive nephropathy — 
16.93 
49.68, 15.83 0.309
Systolic blood pressure 1 mm Hg 1.19 0.34, 2.04 0.006
Diastolic blood pressure 1 mm Hg 
0.62 
2.14, 0.90 0.421
Hematocrit 1% 
365 
597, 
133 0.002
Use of CEI or ARB — 11.31 
13.07, 35.69 0.362
Weekly peritoneal dialysis Kt/V 1 unit 
6.31 
39.15, 26.53 0.705
Glomerular filtration rate 1 mL/min/1.73 m2 
3.04 
9.95, 3.88 0.387
ACE gene DD genotype 13.81 
16.43, 44.04 0.369
AGT gene TT genotype 28.73 5.72, 51.75 0.015
Abbreviations are: CEI, converting-enzyme inhibitor; ARB, angiotensin-receptor blocker; Kt/V, urea clearance; ACE, angiotensin-converting enzyme; AGT,
angiotensinogen.
Table 5. Multivariate analysis showing a significant cross-section relationship between the TT genotype of the AGT M235T gene and relative
wall thickness with adjustment for confounding covariates
Variable Unit change Coefficient 95% Confidence interval P value
Age 1 year 0.001 
0.001, 0.003 0.264
Gender Female 
0.023 
0.074, 0.029 0.386
Body mass index 1 kg/m2 0.001 
0.006, 0.008 0.751
Duration of dialysis 1 month 0.001 0, 0.002 0.020
Diabetes mellitus — 0.004 
0.053, 0.060 0.897
Hypertensive nephropathy — 0.018 
0.053, 0.090 0.609
Systolic blood pressure 1 mm Hg 
0.001 
0.003, 0.001 0.269
Diastolic blood pressure 1 mm Hg 0.001 
0.002, 0.005 0.404
Hematocrit 1% 0.043 
0.461, 0.547 0.867
Use of CEI or ARB — 0.026 
0.027, 0.079 0.327
Weekly peritoneal dialysis Kt/V 1 unit 0.030 
0.041, 0.101 0.410
Glomerular filtration rate 1 mL/min/1.73 m2 
0.005 
0.020, 0.010 0.512
ACE gene DD genotype 0.026 
0.039, 0.092 0.433
AGT gene TT genotype 0.072 0.022, 0.122 0.005
Abbreviations are: CEI, converting-enzyme inhibitor, ARB, angiotensin-receptor blocker; Kt/V, urea clearance; ACE, angiotensin-converting enzyme; AGT,
angiotensinogen.
four (including ours) studies conducted in dialysis pa- relevant than the ACE I/D gene in influencing the sus-
ceptibility to LVH in Chinese ESRD patients. Recenttients, the study by Osono et al [19] showed that the DD
genotype of the ACE gene was related to LV mass in study demonstrated an independent association between
the TT genotype of the AGT gene and greater LVMi indialysis patients when a highly correlative factor, hyper-
tension, was excluded. The other two studies, one in Caucasians with hypertension [40], providing evidence
of genetic linkage between the AGT gene and LV mass.Japanese [38] and the other in Turkish patients [39],
together with our current study, all gave negative results. The functional significance of the AGT M235T gene
polymorphism may contribute to the association be-These discrepant findings are likely explained by inter-
ethnic differences in the frequencies of polymorphisms tween AGT TT genotype and LV mass and remodeling.
The AGT M235T gene polymorphism regulates plasmaof the RAS gene, differences in study methodologies
and population groups as well as confounding factors, AGT levels in both hypertensive [41, 42] and healthy
populations [43]. Those with TT genotype have the high-including blood pressure, diabetes, and gender. The lack
of association between the DD genotype and LV mass est AGT levels, while those with MM genotype the low-
est. AGT is the direct precursor of angiotensin II and isin Chinese ESRD patients may be related to low preva-
lence of the DD genotype (only 15%) compared to Cau- the rate-limiting factor in the renin reaction [44]. Plasma
AGT levels correlate with blood pressure and those withcasians (35%) [22]. On the other hand, the frequency of
the AGT TT genotype was much higher in Chinese high AGT levels are predisposed to hypertension [45, 46].
Previous meta-analysis showed that TT genotype was as-(83%) than Caucasians (30% to 49%) [22, 23], suggesting
polymorphisms of the AGT M235T gene may be more sociated with an increased risk of hypertension in Cauca-
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sians [47]. Our current study showed no significant rela- diabetic patients with DD and TT genotype may de-
crease the likelihood of these patients entering the renaltionship between AGT M235T gene polymorphism and
blood pressure, but it may be that our study was under- replacement program, hence, a lower prevalence of dia-
betes among peritoneal dialysis patients with DD andpowered. It is also possible that TT genotype may con-
tribute to LVH via mechanisms independent of hemody- TT genotype. Further prospective study will be needed
to test this hypothesis. On the other hand, patients withnamic effect. Transgenic mice, overexpressing the AGT
gene in the heart developed myocardial hypertrophy in- DD genotype showed a significantly greater prevalence
of hypertensive nephrosclerosis as the cause of ESRDdependent of the effect of hypertension [48]. This was
evidence to indicate that local angiotensin II production than those with DI or II genotype. However, the exact
implication of this observation is not known.may mediate the hypertrophic response via its trophic ef-
fects on smooth muscle cells and cardiac cells [49]. An extremely high prevalence of LVH (95%) and
more severe hypertrophy were observed in Chinese dial-We also examined possible gene-gene interaction in
relation to the severity of LVH and remodeling. Theoret- ysis patients than Caucasians (75%) [1, 2]. The cause for
this difference is unclear but it is important to note thatically, DD genotype, which is associated with increased
serum ACE activity, together with TT genotype, may some of these studies [1, 2] combined both hemodialysis
and peritoneal dialysis patients, and the echocardio-further promote cardiac growth and LV remodeling by
altering tissue kinin metabolism and increasing angioten- graphic data were obtained shortly after dialysis com-
pared to 37 	 29 months on dialysis in our patients.sin II synthesis and contribute to the higher prevalence
of concentric LVH and greater RWT among patients An earlier study by Takeda et al [53] showed that the
prevalence of LVH was lower in hemodialysis comparedwith the DDTT genotype. The synergistic effect of ACE
I/D and AGT M235T gene polymorphisms was indeed to peritoneal dialysis patients (65% vs. 90%). Study also
suggested that long-term CAPD may be disadvanta-demonstrated in both athletes [50] and patients with
cardiovascular disease [51]. However, in our study we geous in preserving cardiac performance and was associ-
ated with greater LVMi than both short-term CAPDfound no statistical significant interaction between the
ACE DD genotype and the AGT TT genotype. This and hemodialysis [54]. However, even when compared
to Caucasian [2, 55] or Japanese [54] patients on long-may be because our study was not adequately powered
to detect the gene-gene interactive effect with only 25 term peritoneal dialysis, the LVMi of our Chinese pa-
tients were still higher. This raised the possibility thatpatients having the DDTT genotype. Further study with
a much larger sample size will be required to examine racial difference in the frequencies of RAS gene poly-
morphism may contribute to this difference in the preva-possible interactive contribution of the ACE and AGT
gene polymorphisms to LV mass and remodeling in Chi- lence and severity of LVH. As shown in twin studies,
genetic background accounted for a significant propor-nese ESRD patients.
Age, duration of dialysis, systolic blood pressure, and tion of the variation in LV mass [56]. The lower hemoglo-
bin of Chinese (9.4 g/dL) ESRD patients may also partlyanemia were important clinical factors associated with
LVMi in our ESRD patients. However, it is intriguing account for the more severe LVH than Caucasians (10.6
g/dL) [55].to find that the degree of hypertension and anemia had
no significant association with LV remodeling. Only du- No significant difference was noted in the frequencies
of the ACE D allele as well as the AGT T allele betweenration of dialysis was significantly associated with RWT.
The explanation for this observation is unclear but sug- Chinese ESRD patients and controls. This indicates that
the polymorphisms of the ACE I/D gene and AGT M235Tgests LV remodeling in dialysis patients occurs with in-
creasing time on dialysis and is largely independent of gene are probably not primary candidate for susceptibil-
ity to ESRD in Chinese. Our results are in keeping withthe degree of anemia and hemodynamic status. The asso-
ciation between the TT genotype and LVMi, as well as studies showing no increase in the prevalence of DD
genotype in dialysis population as a whole [57]. Recentrelative wall thickness, suggests concentric LVH in
ESRD patients is not only influenced by the interaction study demonstrated a more rapid progression to ESRD
with the DD genotype in the total ESRD population andof hemodynamic, metabolic, and biochemical factors but
also genetic factors. An underrepresentation of the TT with the TT genotype in patients with glomerulonephritis
[58]. This suggests that genes for the RAS may contributeand DD genotype was observed among our ESRD pa-
tients with diabetes mellitus. This is in keeping with to interindividual differences in the rate of progression
to ESRD rather than susceptibility to ESRD.previous studies showing a lower frequency of DD geno-
type with increasing time on dialysis in noninsulin-depen- Our study was mainly limited by the relatively small
sample size, lack of adjustment for potential populationdent diabetes mellitus patients [52] and raised the possi-
bility that the DD and TT genotype may influence stratification bias, cross-sectional study design, study of
prevalent instead of incident patients and also echocardi-survival by contributing to cardiovascular mortality. We
hypothesized that higher cardiovascular mortality among ography was not performed at inception of dialysis. Since
Wang et al: ACE and angiotensinogen gene and cardiac hypertrophy in dialysis patients1906
10. Everett AD, Tufro-McReddie A, Fisher A, Gomez RA: Angio-progressive LVH occurs with longer time on dialysis and
tensin receptor regulates cardiac hypertrophy and transforming
is predictive for mortality, one could argue the possibility growth factor B1 expression. Hypertension 23:587–592, 1994
11. Izumo S, Nadal-Ginard B, Mahdavi V: Protooncogene inductionthat TT genotype may allow longer survival in dialysis
and reprogramming of cardiac gene expression produced by pres-patients despite more severe LVH and the association
sure overload. Proc Natl Acad Sci USA 85:339–343, 1988
between the TT genotype and LVH may be spurious. 12. Harshfieeld GA, Grim CE, Hwang C, et al: Genetic and environ-
mental influences on echocardiographically determined left ven-However, our results did serve as an important pilot
tricular mass in black twins. Am J Hypertens 3:538–543, 1990for further large-scale prospective study with baseline
13. Landry F, Bouchard C, Dumesnil J: Cardiac dimension changes
echocardiography to be performed in order to confirm with endurance training: indications of a genotype dependency.
JAMA 254:77–80, 1985whether the AGT TT genotype is predisposed to more
14. Peters J: Molecular basis of human hypertension: The role ofsevere LVH and remodeling in the Chinese ESRD popu-
angiotensin. Baillieres Clin Endocrinol Metab 9:656–678, 1995
lation. Moreover, since this study included only patients 15. Rigat B, Hubert C, Alhenc-Gelas F, et al: An insertion deletion
polymorphism in angiotensin I converting enzyme gene accountingon peritoneal dialysis, it needs further study to decide
for half the variance of serum enzyme levels. J Clin Invest 86:1343–whether the results can also be generalized to patients
1346, 1990
on hemodialysis. 16. Schunkert H, Hense HW, Holmer SR, et al: Association between
a deletion polymorphism of the angiotensin-converting enzymeIn conclusion, the TT genotype of the AGT M235T
gene and left ventricular hypertrophy. N Engl J Med 330:1634–gene is associated with greater LV mass and increased
1638, 1994
risk of concentric LVH in Chinese ESRD patients. Given 17. Marian AJ, Yu QT, Worman R, et al: Angiotensin-converting
enzyme polymorphism in hypertrophic cardiomyopathy and sud-the high prevalence of LVH in ESRD patients and the
den cardiac death. Lancet 342:1085–1086, 1993important association between concentric LVH and mor-
18. Cambien F, Poirier O, Lecerf L, et al: Deletion polymorphism in
tality, further study will be needed to determine if the the gene for angiotensin converting enzyme is a potent risk factor
for myocardial infarction. Nature 359:641–644, 1992AGT M235T gene polymorphism with or without inter-
19. Osono E, Kurihara S, Hayama N, et al: Insertion/deletion poly-action with ACE I/D gene polymorphism influence sur-
morphism in intron 16 of the ACE gene and left ventricular hyper-
vival in ESRD patients. trophy in patients with end-stage renal disease. Am J Kidney Dis
32:725–730, 1998
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